Serina Therapeutics
在场
Serina Therapeutics 的所有者是 Lineage Cell Therapeutics.
是其中之一......
Lineage Cell Therapeutics 是一家在股票代码 LCTX (US) 下上市的公司。
Lineage Cell Therapeutics 拥有 3家子公司，其中包括 ESI Bio、OncoCyte 和 Serina Therapeutics。
高管
查看带有其 10 名主要高管的组织结构图
Serina Therapeutics 搜索最多的简介
- Steve Ledger, Interim Chief Executive Officer and Director
- Richard Marshall, Director
- Remy Gross, Director
高管在Serina Therapeutics变化
- Tacey Viegas, Chief Operating Officer, 正在办理退休 (新闻发布的2024七月22号).
- Srini Tenjarla已作为Senior Vice President of Chemistry, Manufacturing, Controls, Product Development and Formulation加入公司 (新闻发布的2024七月20号).
- Simba Gill已作为Executive Chairman of the Board加入公司 (新闻发布的2024四月18号).
高管在Lineage Cell Therapeutics变化
- Michael Mulroy 曾任 Director, 现升职为 Chairman of the Board (新闻发布的2024四月30号).
- Alfred Kingsley, Chairman of the Board, 已经去世。我们深感遗憾 (新闻发布的2024四月30号).
- Charlotte Hubbert已作为Vice President of Corporate Development加入公司 (新闻发布的2024四月2号).
创建提醒
跟踪 Serina Therapeutics 的高管变动
生物技术
Lineage Cell Therapeutics 拥有 2,337 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
- OraSure Technologies has announced the acquisition of Sherlock Biosciences (公布2024十二月20号).
- SiteOne Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Serina Therapeutics 的最新新闻稿
- Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
- Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
- Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
- Serina Therapeutics to Present at the 14th Annual Injectables Summit
- Enable Injections Announces Agreement with Sobi® to Develop and Distribute Aspaveli® in Combination with enFuse® in Sobi Territories
- Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
- Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
- AgeX Therapeutics | single-news-story
- AgeX Therapeutics | single-news-story
- View more press releases Close
通过电子邮件
